print page


A corporate fact sheet on Clinuvel can be downloaded here (pdf format).

How can I invest in Clinuvel?

Clinuvel Pharmaceuticals Limited is listed on the Australian Stock Exchange (ASX) under the symbol CUV, Clinuvel does not issue stocks directly to investors. Please contact a financial advisor for more investing information.

How can I subscribe to Clinuvel's email updates?

Clinuvel maintains regular contact with our stakeholders via our email updates. Click here to subscribe.

Why is CUV1647 not currently available on the market?

CUV1647 is in its development phase and not currently available on the market. It is currently being tested for its safety and efficacy in clinical trials.

In ethical pharmaceutical drug development a rigorous clinical program needs to be followed to comply with the requirements of regulators worldwide. Drug development therefore is not a speedy process. It takes time. 

Ensuring the safety and efficacy of CUV1647 is paramount to the program and Clinuvel is following an intensive clinical trial process in advance of pursuing regulatory approval and commercialisation to make this process as fast as possible.

What conditions does CUV1647 aim to treat?

Clinuvel’s pioneering work aims at assisting those who suffer from three UV related skin disorders and two cancer related treatments. The five clinical indications that Clinuvel are currently testing CUV1647 for:

  • Squamous Cell Carcinoma (SCC) - non-melanoma skin cancers – and Actinic Keratosis (AK), a precursor to skin cancers, in organ transplant patients.  Organ transplant patients who are fair skinned are 65 to 100 times more likely to develop skin cancer on prescribed immune-suppressant medication following their transplant, compared to the general population.
  • Phototoxicity associated with Photodynamic Therapy (PDT) for cancer – a debilitating photosensitivity to sunlight and artificial light (skin and eyes) that can last up to 90 days after PDT treatment
  • Erythropoietic Protoporphyria (EPP) - absolute sun intolerance, intolerable pain suffered when exposed to light by between one in 200,000 and one in 750,000.
  • Polymorphous Light Eruption (PMLE) – likened to sun poisoning. Suffered by 10 -20% of Population
  • Solar Urticaria (SU) – (acute) anaphylactic reaction to sun

Could CUV1647 be used to treat Vitiligo?

Clinuvel is not currently testing for the indication of Vitiligo, and at present no clinical trials are planned for the foreseeable future. By subscribing to our database, you will receive company updates on any clinical trials.

How is CUV1647 administered?

It is anticipated that CUV1647 will be administered by medical practitioners and delivered underneath the skin as a biodegradable implant that is approximately the size of a grain of rice.  This type of administration allows the dosage of the drug to be carefully measured by the medical practitioners who prescribes it.

Will CUV1647 give me a tan?

CUV1647 is not a cosmetic tanning product.

Clinuvel believes that CUV1647 has the potential to increase the quality of life of the many millions of people worldwide who suffer from skin disorders and damage caused by UV radiation.  Clinuvel is targeting a global problem that affects millions of people. We strongly support government and health care providers in their initiative to increase education about the dangers to UV-radiation and recommends that people follow their advice.

How can I register to take part in trials?

The clinical trials that Clinuvel are currently conducting for CUV1647 are in specific patient groups. As with all clinical studies there are strict inclusion and exclusion criteria for participating patients and only patients with designated diseases who meet these criteria are eligible for entry. By subscribing to our database, you will receive company updates on any clinical trials and the conditions of participation.

What is Melanotan II?

Melanotan II is a very different peptide to CUV1647 and has no connection to Clinuvel Pharmaceuticals Limited. As a Pharmaceutical company, we do not encourage experimenting with un-registered drugs.

Can I already buy Melanotan I and other such products online?

Clinuvel is aware of the unregistered products and various products offered illegally to the online audience.

These products have no resemblance or equivalence to our drug CUV1647. It may well be that the vendors make false claims, advertise with proprietary material belonging to Clinuvel, and/or use the name of the Clinuvel brand (formerly Epitan) to offer you these illegal products. Clinuvel takes no responsibility for these products and warns against the use of these, as they may pose a safety hazard and long-term risk to humans.

Clinuvel Pharmaceuticals Ltd is currently taking legal action with the help of global regulators, such as FDA, against the companies selling illegal products that may be promoted or solicited to act similar to Clinuvel's drug in development CUV1647. Clinuvel warns that the products offered on these websites may contain substances and/or ingredients that may cause long-term harm to human health.

2007 Annual Report UV Widget